Sign in
Taking peopleNo phase

Studies pregnancy outcomes in people with lupus or antiphospholipid syndrome

Observes pregnant adults with lupus or antiphospholipid syndrome to see what predicts pregnancy problems.

Key facts

Who runs it
Hospital for Special Surgery, New York
Where
London, United KingdomSee the siteAlso in 2 other countries, 9 sites
Trial code
Registry title
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
Status
Recruiting
People taking part
700 people, planned
Started
Sept 2003
Expected to end
Mar 2027
Type of study
Observational, 4 groups
Record updated
28 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for pregnant women who have lupus (SLE), antiphospholipid antibodies, both, or neither (healthy controls). It follows how the pregnancy goes.

Age
18 to 45 years; under 18 can join with parental consent.
Sex
Women only (pregnant).
Disease stage
Live pregnancy of up to 12 weeks (no aPL antibodies) or up to 18 weeks (with aPL antibodies). Groups: aPL antibodies without SLE, aPL antibodies with SLE, SLE without aPL antibodies, and healthy controls.
Biomarker or test result
Positive aPL antibodies means a positive LAC, or aCL IgG or IgM at 40 units or more, or anti-β2GPI IgG or IgM at 40 units or more. Controls must have no positive aPL.

Main reasons for not taking part

  • Diabetes (type I or type II) that started before the pregnancy
  • Known or suspected inherited complement deficiency (CH50 = 0)
  • Controls: a past fetal death, or more than 1 miscarriage before 10 weeks
  • Controls: currently smoking or a medical problem needing long-term treatment
  • Hematocrit of 26% or lower

This trial only enrols pregnant participants. The registry sentence this rests on: Patient pregnant with live intrauterine pregnancy, as defined by positive test for elevated β-HCG, but ≤ 12 weeks by gestation (for subjects without aPL antibodies) and ≤18 weeks (for subjects with aPL antibodies)

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Patient pregnant with live intrauterine pregnancy, as defined by positive test for elevated β-HCG, but ≤ 12 weeks by gestation (for subjects without aPL antibodies) and ≤18 weeks (for subjects with aPL antibodies)
  • Patient between the ages of 18-45 and able to give informed consent, or age < 18 years with parental consent
  • Hematocrit > 26%
  • For APL positive:; aCL: IgG >= 40 GPL units; IgM >= 40 MPL units; Positive LAC (RVVT, Kaolin, dilute TTI or PTT LA); Anti-β2GPI: IgG >= 40 GPL units; IgM >= 40 MPL units
  • For control subjects:; At least one successful pregnancy; No history of fetal death (death of conceptus ≥ 10 weeks' gestation); No more than 1 miscarriage < 10 weeks' gestation; No history of positive aPL in local lab or positive aPL in core labs at screening; Not currently a smoker; No medical problems requiring chronic treatment

Who cannot take part

  • Diabetes mellitus (Type I and Type II) antedating pregnancy
  • Known or suspected hereditary complement deficiency (defined by CH50 = 0)

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 45 years old?

Where in United Kingdom

Also in 2 other countries, 9 sites

  • Guy's & St Thomas' NHS Foundation TrustLondon, United KingdomContact: Marta M. Guerra, MSNo longer taking part

About the trial

What the trial wants to find out

The PROMISSE Study is an observational study of 700 pregnant patients, enrolled at nine major clinical centers. The purpose of the study is 1) to determine whether certain proteins (called complement split products) that can injure healthy organs can be used to predict poor pregnancy outcome in patients with systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS), and/or 2) to determine whether elevated levels of circulating antiangiogenic factors predict pregnancy complications in patients with aPL antibodies and/or SLE.

The 4 groups in the trial

  • Group 1: aPL+/SLE-

    Positive antiphospholipid antibodies (aPL) defined as positive LAC and/or anti cardiolipin IgG/IgM \>= 40 units and/or anti-beta 2 glycoprotein I IgG or IgM \>= 40 units; no SLE

  • Group 2: aPL+/SLE+

    Positive antiphospholipid antibodies (aPL) defined as positive LAC and/or anti cardiolipin IgG/IgM \>= 40 units and/or anti-beta 2 glycoprotein I IgG or IgM \>= 40 units AND SLE defined as four or more American College of Rheumatology criteria for SLE.

  • Group 3: aPL-/SLE+

    No antiphospholipid antibodies; SLE defined as four or more American College of Rheumatology criteria for SLE.

  • Group 4: aPL-/SLE-

    Healthy controls: no antiphospholipid antibodies; no SLE

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
Plain-language title
Studies pregnancy outcomes in people with lupus or antiphospholipid syndromeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT00198068, who can take part
Publications
Record updated
28 April 2026